Epic Bio Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform Leadership at ASGCT Annual Meeting
23. April 2024 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today shared details of...
Epic Bio to Participate in a Fireside Chat at the Cantor Virtual Muscular Dystrophy Symposium
01. April 2024 16:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber...
Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit
13. März 2024 16:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber...
FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
16. November 2023 06:00 ET
|
Epic Bio
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root...
Epic Bio to Participate in Upcoming Investor Conference
07. November 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
19. Oktober 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
17. Oktober 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society
28. September 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event
19. September 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators
14. September 2023 12:00 ET
|
Epic Bio
- Vast high-throughput screening study used to train unique machine learning algorithm to design synthetic activators - - Rational engineering produced activators that induce the most...